These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The complex clinical picture of side effects to biologicals. Hausmann OV; Seitz M; Villiger PM; Pichler WJ Med Clin North Am; 2010 Jul; 94(4):791-804, xi-ii. PubMed ID: 20609863 [TBL] [Abstract][Full Text] [Related]
3. The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification. Zemková M; Jebavý L; Kotlárová J; Vlcek J; Meyboom RH Folia Biol (Praha); 2007; 53(4):146-55. PubMed ID: 17706021 [TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of adverse drug reactions to biologics. Clarke JB Handb Exp Pharmacol; 2010; (196):453-74. PubMed ID: 20020272 [TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity reactions during treatment with biological agents. Puxeddu I; Caltran E; Rocchi V; Del Corso I; Tavoni A; Migliorini P Clin Exp Rheumatol; 2016; 34(1):129-32. PubMed ID: 26751942 [TBL] [Abstract][Full Text] [Related]
7. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Vermeire S; Van Assche G; Rutgeerts P Best Pract Res Clin Gastroenterol; 2009; 23(1):101-12. PubMed ID: 19258190 [TBL] [Abstract][Full Text] [Related]
9. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Khawli LA; Hu P; Epstein AL Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951 [TBL] [Abstract][Full Text] [Related]
10. Factors influencing the immunogenicity of therapeutic proteins. Schellekens H Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi3-9. PubMed ID: 15958824 [TBL] [Abstract][Full Text] [Related]
11. Adverse drug reactions to biologics. Scherer K; Spoerl D; Bircher AJ J Dtsch Dermatol Ges; 2010 Jun; 8(6):411-26. PubMed ID: 20136676 [TBL] [Abstract][Full Text] [Related]
12. Hazard identification and risk assessment for biologics targeting the immune system. Weir AB J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852 [TBL] [Abstract][Full Text] [Related]
13. [Allergy-immunology. Do we have to be afraid of biological agents?]. Bart PA Rev Med Suisse; 2011 Jan; 7(278):106-7. PubMed ID: 21400939 [TBL] [Abstract][Full Text] [Related]
14. Developments in systemic immunomodulatory therapy for psoriasis. Berger EM; Gottlieb AB Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886 [TBL] [Abstract][Full Text] [Related]
15. Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity. Pichler WJ; Daubner B; Kawabata T J Dermatol; 2011 Mar; 38(3):216-21. PubMed ID: 21342222 [TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity reactions to biological drugs. Corominas M; Gastaminza G; Lobera T J Investig Allergol Clin Immunol; 2014; 24(4):212-25; quiz 1p following 225. PubMed ID: 25219103 [TBL] [Abstract][Full Text] [Related]
17. Immune mechanism of drug hypersensitivity. Pichler WJ Immunol Allergy Clin North Am; 2004 Aug; 24(3):373-97, v-vi. PubMed ID: 15242717 [TBL] [Abstract][Full Text] [Related]
19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
20. [Important side effects of non-steroidal antirheumatic agents]. Kolarz G Wien Med Wochenschr; 1982 Dec; 132(23-24):592-5. PubMed ID: 7164470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]